College of Automation Engineering, Nanjing University of Aeronautics and Astronautics, Nan Jing, Jiang Su, China.
Department of Mechanical Engineering, University of California Berkeley, Berkeley CA, United States of America.
Radiol Oncol. 2023 Sep 4;57(3):279-291. doi: 10.2478/raon-2023-0044. eCollection 2023 Sep 1.
BACKGROUND: Tumor Treating Fields (TTFields) is a non-invasive modality for cancer treatment that utilizes a specific sinusoidal electric field ranging from 100 kHz to 300 kHz, with an intensity of 1 V/cm to 3 V/cm. Its purpose is to inhibit cancer cell proliferation and induce cell death. Despite promising outcomes from clinical trials, TTFields have received FDA approval for the treatment of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM). Nevertheless, global acceptance of TTFields remains limited. To enhance its clinical application in other types of cancer and gain a better understanding of its mechanisms of action, this review aims to summarize the current research status by examining existing literature on TTFields' clinical trials and mechanism studies. CONCLUSIONS: Through this comprehensive review, we seek to stimulate novel ideas and provide physicians, patients, and researchers with a better comprehension of the development of TTFields and its potential applications in cancer treatment.
背景：肿瘤治疗电场（TTFields）是一种非侵入性的癌症治疗方式，利用特定的正弦电场，频率在 100 kHz 到 300 kHz 之间，强度在 1 V/cm 到 3 V/cm。其目的是抑制癌细胞增殖并诱导细胞死亡。尽管临床试验结果令人鼓舞，但 TTFields 已获得美国食品药品监督管理局（FDA）批准用于治疗多形性胶质母细胞瘤（GBM）和恶性胸膜间皮瘤（MPM）。然而，TTFields 在全球范围内的接受程度仍然有限。为了增强其在其他类型癌症中的临床应用，并更好地了解其作用机制，本综述通过检查 TTFields 临床试验和机制研究的现有文献，旨在总结当前的研究现状。
结论：通过全面综述，我们希望激发新的思路，并为医生、患者和研究人员提供更好地理解 TTFields 的发展及其在癌症治疗中的潜在应用。
Expert Rev Mol Diagn. 2022-1
Chin Clin Oncol. 2023-12
Crit Rev Oncol Hematol. 2021-12
Tissue Eng Part B Rev. 2023-6
Cancers (Basel). 2022-6-15
Adv Radiat Oncol. 2021-5-17
Front Oncol. 2020-10-30
Zotero 插件
